ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 2, 2015, Pages 134-138

  Houang, Michelle ^a,b,c   Toon, Christopher W ^a,c,d   Clarkson, Adele ^a,b   Sioson, Loretta ^a,b   De Silva, Keshani ^b   Watson, Nicole ^a   Singh, Nisha R ^b   Chou, Angela ^e   Gill, Anthony J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Histopath Pathology   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

ALK; colorectal carcinoma; crizotinib; EMLR ALK translocation; ROS1; ROS1 translocations

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN; PROTEIN ROS1; UNCLASSIFIED DRUG; CRIZOTINIB; EML4-ALK FUSION PROTEIN, HUMAN; FIG-ROS1 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; COLORECTAL CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; ADENOCARCINOMA; COHORT ANALYSIS; COLORECTAL NEOPLASMS; DIAGNOSTIC TEST; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADENOCARCINOMA; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY;

EID: 84924527124     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000025     Document Type: Article

References (14)

1. D'Arcangelo M, Wynes MW, Hirsch FR. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 2013;25:121-129
2. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013;8: 322-328
3. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-1553
4. Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013;37:1441-1449
5. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457
6. Bowden E, Eddy S, Williams P, et al. A survey of thousands of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib. J Clin Oncol. 2013;31(15-suppl (May 20 supplement)
7. Lin E. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7:1466-1476
8. Weickhardt AJ, Nguyen TN, Paskulin DD, et al. ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH). J Clin Oncol. 2013; 31(15-suppl)
9. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013;37: 1592-1602
10. Toon CW, Chou A, Desilva K, et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2013. [Epub ahead of print]
11. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 2010
12. Han XH, Zhang NN, Ma L, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-smallcell lung cancer. Virchows Arch. 2013;463:583-591
13. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALKrearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16:1561-1571
14. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.